ERBB4 and non-small cell lung carcinoma: Poziotinib is an oral, third-generation, quinazoline-based inhibitor of epidermal growth factor receptors (EGFR, HER2, and HER4) that Hanmi Pharmaceutical has developed, currently being investigated in phase II clinical trials for breast and non-small cell lung cancer treatment [105].